Naziyet Köse Baytemür
A5004317421- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Bladder and Urothelial Cancer Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
Memorial Ankara Hospital
2020-2024
Üsküdar University
2021
There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which oncologists prefer patients with disease progression under CDKi. In addition, we show the effectiveness of systemic treatments CDKi and whether there a survival difference between hormonal (monotherapy vs. mTOR-based).A total 609 from 53 centers were included study....
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase as the first-line standard-of-care for patients hormone receptor-positive, HER2-negative metastatic breast cancer.
Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in general population that is not limited by selection criteria clinical studies. The aim this study was to evaluate palbociclib or ribociclib plus fulvestrant hormone receptor-positive human epidermal factor 2-negative metastatic breast cancer (HR+/HER2-MBC). We conducted a multicenter, retrospective cohort included 522 patients with HR+/HER2-MBC treated combination fulvestrant....
Aims: In this multicenter study, the authors aimed to determine real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with alectinib in terms ALK-tyrosine kinase inhibitors, regardless previous chemotherapy. The co-primary end points progression-free survival both for all treatment-naive population. secondary overall response rate, survival, rate CNS...
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there no comprehensive study on which platinum-based should be preferred. This aimed to compare response and survival characteristics patients with or gastroesophageal junction (GEJ) cancer who received fluorouracil, oxaliplatin, leucovorin (mFOLFOX)+trastuzumab cisplatin fluorouracil (CF)+trastuzumab as therapy. It was a...
Abstract Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that percentage tumor cells patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether had a predictive effect NSCLC who received as ALK-TKI. Materials and Methods: retrospective included advanced-stage alectinib ALK-TKI whose was determined by...
e15587 Background: Expanded RAS analysis is essential for the selection of biologic agents in mCRC. mutations indicates anti-EGFR unresponsiveness. In this study, we aimed to investigate and BRAF by liquid biopsy at progression patients with mutant Methods: Sixty mCRC who harbored tissue were prospectively analyzed between July 2019 April 2020. All treated chemotherapy plus bevacizumab combinations . The plasma samples after combinations. mutation profile was evaluated using Idylla PCR-based...